BioCentury | Feb 22, 2020
Management Tracks

Everest names new CEO; plus Merck, Gilead, Turning Point, Adaptimmune, AskBio and more

Everest Medicines Ltd. hired Kerry Blanchard as CEO. Blanchard, who will also join the company’s board, succeeds interim CEO Sean Cao. Blanchard was an operating partner at Everest’s founding investor CBC Group and previously served...
BioCentury | Feb 14, 2020
Product Development

Feb. 13 Product Development Quick Takes: Priority Review for BMS, Seattle Genetics, Deciphera therapies; plus Roche, Ipsen, Merck, Eisai and Amgen-Pfizer

August decision dates for BMS, Seattle Genetics, Deciphera  A trio of cancer therapies have received Priority Review from FDA with August PDUFA dates. Bristol-Myers Squibb Co. (NYSE:BMY) said FDA accepted a BLA for lisocabtagene maraleucel...
BC Extra | Jan 17, 2020
Company News

Management tracks: Sun departs as Hengrui chair; plus Blackstone, Ipsen, bluebird, BioNTech, Catalent, Foundation, Twist, Lantheus, Abcam and more

Jiangsu Hengrui Medicine Co Ltd. (Shanghai:600276) said Piaoyang Sun will step down as chairman. Sun, who has led the company for 30 years, will continue to serve on the board’s strategy committee and is succeeded...
BioCentury | Jan 11, 2020
Finance

Why buysiders say 2020 could be the year of the CNS

A pair of CNS approvals in the final days of 2019 has only added to the growing momentum buysiders were already tracking for 2020 in the once neglected disease area. Positive regulatory signals are converging...
BC Extra | Dec 26, 2019
Company News

Dec. 27 Company Quick Takes: Immunomedics, Qiagen, Eisai-Gilead, Melinta, Denovo-Rumpus

FDA again reviewing Immunomedics’ ADC  FDA has accepted a resubmitted BLA from Immunomedics Inc. (NASDAQ:IMMU) seeking accelerated approval of sacituzumab govitecan to treat third-line metastatic triple-negative breast cancer. The company had received a complete response...
BC Extra | Dec 24, 2019
Company News

Regulatory roundup: BioMarin poised to have first U.S., EU hemophilia gene therapy; plus Allergan, Eisai, FibroGen, ViiV and Vero

Monday's basket of regulatory news includes two landmark regulatory applications for BioMarin's hemophilia gene therapy in the U.S. and EU, and FDA approval of Allergan's migraine drug. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) submitted a BLA to...
BC Extra | Dec 6, 2019
Clinical News

Biogen Alzheimer’s data won’t sway believers or doubters either way

The upshot of Biogen’s aducanumab data is that the robustness of the compound’s efficacy remains in doubt. The CTAD presentation gave enough grist for believers to continue believing and skeptics to keep on doubting. Aducanumab...
BC Innovations | Nov 15, 2019
Product Development

Minerva on the verge in neuropsychiatry with two compounds close to verdict

Minerva Neurosciences is on the precipice of two clinical readouts that could determine whether its founding bet on a pair of neuropsychiatry compounds from Mitsubishi Tanabe has panned out. Neither molecule represents a shift from...
BC Extra | Nov 12, 2019
Company News

Skyhawk’s $80M Celgene deal expands remit to autoimmune

In Skyhawk’s fifth deal of the year, the company is moving into a new therapeutic area and adding $80 million to its cash reserve. Skyhawk partnered with Celgene to discover and develop small molecules for...
BC Extra | Nov 7, 2019
Financial News

Nov. 6 Financial Quick Takes: NEA backs Shape's series A; plus Royalty-Eisai-Epizyme, Sinomed, Genecast and Cadence

Shape raises $35.5M A round  RNA editing company Shape Therapeutics Inc. raised $35.5 million in a series A round led by New Enterprise Associates, with participation from CureDuchenne Ventures. The company uses guide RNAs to...
Items per page:
1 - 10 of 1842
BioCentury | Feb 22, 2020
Management Tracks

Everest names new CEO; plus Merck, Gilead, Turning Point, Adaptimmune, AskBio and more

Everest Medicines Ltd. hired Kerry Blanchard as CEO. Blanchard, who will also join the company’s board, succeeds interim CEO Sean Cao. Blanchard was an operating partner at Everest’s founding investor CBC Group and previously served...
BioCentury | Feb 14, 2020
Product Development

Feb. 13 Product Development Quick Takes: Priority Review for BMS, Seattle Genetics, Deciphera therapies; plus Roche, Ipsen, Merck, Eisai and Amgen-Pfizer

August decision dates for BMS, Seattle Genetics, Deciphera  A trio of cancer therapies have received Priority Review from FDA with August PDUFA dates. Bristol-Myers Squibb Co. (NYSE:BMY) said FDA accepted a BLA for lisocabtagene maraleucel...
BC Extra | Jan 17, 2020
Company News

Management tracks: Sun departs as Hengrui chair; plus Blackstone, Ipsen, bluebird, BioNTech, Catalent, Foundation, Twist, Lantheus, Abcam and more

Jiangsu Hengrui Medicine Co Ltd. (Shanghai:600276) said Piaoyang Sun will step down as chairman. Sun, who has led the company for 30 years, will continue to serve on the board’s strategy committee and is succeeded...
BioCentury | Jan 11, 2020
Finance

Why buysiders say 2020 could be the year of the CNS

A pair of CNS approvals in the final days of 2019 has only added to the growing momentum buysiders were already tracking for 2020 in the once neglected disease area. Positive regulatory signals are converging...
BC Extra | Dec 26, 2019
Company News

Dec. 27 Company Quick Takes: Immunomedics, Qiagen, Eisai-Gilead, Melinta, Denovo-Rumpus

FDA again reviewing Immunomedics’ ADC  FDA has accepted a resubmitted BLA from Immunomedics Inc. (NASDAQ:IMMU) seeking accelerated approval of sacituzumab govitecan to treat third-line metastatic triple-negative breast cancer. The company had received a complete response...
BC Extra | Dec 24, 2019
Company News

Regulatory roundup: BioMarin poised to have first U.S., EU hemophilia gene therapy; plus Allergan, Eisai, FibroGen, ViiV and Vero

Monday's basket of regulatory news includes two landmark regulatory applications for BioMarin's hemophilia gene therapy in the U.S. and EU, and FDA approval of Allergan's migraine drug. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) submitted a BLA to...
BC Extra | Dec 6, 2019
Clinical News

Biogen Alzheimer’s data won’t sway believers or doubters either way

The upshot of Biogen’s aducanumab data is that the robustness of the compound’s efficacy remains in doubt. The CTAD presentation gave enough grist for believers to continue believing and skeptics to keep on doubting. Aducanumab...
BC Innovations | Nov 15, 2019
Product Development

Minerva on the verge in neuropsychiatry with two compounds close to verdict

Minerva Neurosciences is on the precipice of two clinical readouts that could determine whether its founding bet on a pair of neuropsychiatry compounds from Mitsubishi Tanabe has panned out. Neither molecule represents a shift from...
BC Extra | Nov 12, 2019
Company News

Skyhawk’s $80M Celgene deal expands remit to autoimmune

In Skyhawk’s fifth deal of the year, the company is moving into a new therapeutic area and adding $80 million to its cash reserve. Skyhawk partnered with Celgene to discover and develop small molecules for...
BC Extra | Nov 7, 2019
Financial News

Nov. 6 Financial Quick Takes: NEA backs Shape's series A; plus Royalty-Eisai-Epizyme, Sinomed, Genecast and Cadence

Shape raises $35.5M A round  RNA editing company Shape Therapeutics Inc. raised $35.5 million in a series A round led by New Enterprise Associates, with participation from CureDuchenne Ventures. The company uses guide RNAs to...
Items per page:
1 - 10 of 1842